BIOA Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

3 Analyst Rating

Wall Street analysts forecast BIOA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BIOA is 13.50 USD with a low forecast of 12.00 USD and a high forecast of 15.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

2 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

12.00

Averages

13.50

High

15.00

Current: 0.000

Low

12.00

Averages

13.50

High

15.00

Morgan Stanley

Underweight -> Equal Weight

upgrade

$5 -> $12

2025-12-05

Reason

Morgan Stanley

Price Target

$5 -> $12

2025-12-05

upgrade

Underweight -> Equal Weight

Reason

Morgan Stanley upgraded BioAge Labs to Equal Weight from Underweight with a price target of $12, up from $5, after the company announced interim Phase 1 data for BGE-102, including safety info and data from single and multiple ascending doses up to 120mg in healthy volunteers. The initial "encouraging" clinical data for BGE-102 highlights robust biomarker reductions, suggesting potential to reduce cardiovascular risk, contends the analyst, who will look to additional data in 2026 for further confirmation.

Citi

Buy

upgrade

$10 -> $15

2025-10-29

Reason

Citi

Price Target

$10 -> $15

2025-10-29

upgrade

Buy

Reason

Citi raised the firm's price target on BioAge Labs to $15 from $10 and keeps a Buy rating on the shares. The firm adjusted biotech price targets as part of a Q3 earnings preview.

Citi

Neutral -> Buy

upgrade

$5 -> $10

2025-10-22

Reason

Citi

Price Target

$5 -> $10

2025-10-22

upgrade

Neutral -> Buy

Reason

Citi upgraded BioAge Labs to Buy from Neutral with a price target of $10, up from $5. The firm believes the company's BGE-102 can become a "differentiated" NLRP3 inhibitor in treating obesity.

Citi

Samantha Semenkow

Neutral -> Buy

upgrade

$5 -> $10

2025-10-22

Reason

Citi

Samantha Semenkow

Price Target

$5 -> $10

2025-10-22

upgrade

Neutral -> Buy

Reason

Citi analyst Samantha Semenkow upgraded BioAge Labs to Buy from Neutral with a price target of $10, up from $5. The firm believes the company's BGE-102, an oral NLRP3 inhibitor being developed for obesity, could be "differentiating." BGE-102 is a "potentially differentiated" NLRP3 inhibitor that could be given in combination with oral GLP1s or be a monotherapy, the analyst tells investors in a research note.

Citigroup

Samantha Semenkow

Hold

Maintains

$7 → $5

2025-03-24

Reason

Citigroup

Samantha Semenkow

Price Target

$7 → $5

2025-03-24

Maintains

Hold

Reason

Citi analyst Samantha Semenkow lowered the firm's price target on BioAge Labs to $5 from $7 and keeps a Neutral rating on the shares post the Q4 report. The firm anticipates the shares will remain somewhat range-bound over the next 12 months given "limited stock-moving catalysts."

Morgan Stanley

Jeffrey Hung

Sell

Initiates

2025-03-07

Reason

Morgan Stanley

Jeffrey Hung

Price Target

2025-03-07

Initiates

Sell

Reason

Morgan Stanley assumed coverage of BioAge Labs with an Underweight rating and $5 price target following the recent pipeline setback resulting in the discontinuation of lead program azeleprag. While the firm believes the pipeline may have potential, development remains in the early stages and Morgan Stanley awaits greater clarity.

Valuation Metrics

The current forward P/E ratio for BIOAGE Labs Inc (BIOA.O) is -4.76, compared to its 5-year average forward P/E of -2.99. For a more detailed relative valuation and DCF analysis to assess BIOAGE Labs Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-2.99

Current PE

-4.76

Overvalued PE

-0.95

Undervalued PE

-5.02

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.18

Current EV/EBITDA

-1.63

Overvalued EV/EBITDA

3.09

Undervalued EV/EBITDA

-2.73

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

34.04

Current PS

91.55

Overvalued PS

63.27

Undervalued PS

4.82

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

BIOA News & Events

Events Timeline

No data

News

9.5

01-07Benzinga

Penguin Solutions Reports Q1 Earnings of $0.49, Shares Up 5.3%

9.0

01-06Newsfilter

BioArctic and Eisai's Leqembi BLA Accepted in China for Subcutaneous Use

9.0

01-06PRnewswire

BioArctic and Eisai's Leqembi Injection Application Accepted in China

People Also Watch

Frequently Asked Questions

What is BIOAGE Labs Inc (BIOA) stock price today?

The current price of BIOA is 14.03 USD — it has increased 0.79 % in the last trading day.

What is BIOAGE Labs Inc (BIOA)'s business?

BioAge Labs, Inc. is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its lead product is BGE-102, a structurally novel, orally available small molecule NLRP3 inhibitor with high potency and brain penetration. In preclinical obesity models, BGE-102 resulted in weight loss as both a monotherapy and in combination with a GLP-1R agonist. Its pipeline includes novel, orally available, brain-penetrant small-molecule NLRP3 inhibitors to treat metabolic diseases and conditions driven by neuroinflammation, as well as novel APJ agonists for metabolic disorders. In preclinical obesity models, APJ agonism has demonstrated the ability to more than double the weight loss induced by a GLP-1R agonist while also restoring healthy body composition and improving muscle function.

What is the price predicton of BIOA Stock?

What is BIOAGE Labs Inc (BIOA)'s revenue for the last quarter?

BIOAGE Labs Inc revenue for the last quarter amounts to 2.05M USD, decreased % YoY.

What is BIOAGE Labs Inc (BIOA)'s earnings per share (EPS) for the last quarter?

BIOAGE Labs Inc. EPS for the last quarter amounts to -0.56 USD, decreased -18.84 % YoY.

What changes have occurred in the market's expectations for BIOAGE Labs Inc (BIOA)'s fundamentals?

The market is revising Upward the revenue expectations for BioAge Labs, Inc. (BIOA) for FY2025, with the revenue forecasts being adjusted by 37.92% over the past three months. During the same period, the stock price has changed by 162.24%.

How many employees does BIOAGE Labs Inc (BIOA). have?

BIOAGE Labs Inc (BIOA) has 62 emplpoyees as of January 10 2026.

What is BIOAGE Labs Inc (BIOA) market cap?

Today BIOA has the market capitalization of 503.05M USD.